title: Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients.
authors.affiliation: Farmacia, Hospital Universitari de Bellvitge, España.
authors.forename: Eugènia
authors.initials: E
authors.lastname: Santacana Juncosa
authors.affiliation: Farmacia, Hospital de Bellvitge, España.
authors.forename: Ariadna
authors.initials: A
authors.lastname: Padullés Zamora
authors.affiliation: Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia (Universidad de Barcelona), España.
authors.forename: Helena
authors.initials: H
authors.lastname: Colom Codina
authors.affiliation: Aparato digestivo, Hospital de Bellvitge, España.
authors.forename: Lorena
authors.initials: L
authors.lastname: Rodríguez Alonso
authors.affiliation: Hospital Universitari Bellvitge. Idibell. Hospitalet de Llobregat, Barcelona.
authors.forename: Jordi
authors.initials: J
authors.lastname: Guardiola Capo
authors.affiliation: Hospital Universitari Bellvitge. Idibell. Hospitalet de Llobregat, Barcelona.
authors.forename: Jordi
authors.initials: J
authors.lastname: Bas Minguet
authors.affiliation: FARMACIA, Hospital Universitari Bellvitge. Idibell. Hospitalet de Llobregat, Barcelona, ESPAÑA.
authors.forename: Núria
authors.initials: N
authors.lastname: Padullés Zamora
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab